RxSight announces $40M common stock offering

RxSight announced that it intends to offer and sell, subject to market and other conditions, $40M of shares of its common stock in an underwritten public offering. RxSight intends to use the net proceeds of the offering for continued commercial and marketing expansion, funding of product development, research and clinical development, and for working capital and general corporate purposes. BofA Securities is acting as the sole bookrunning manager for the offering.